Manufacturing processes, scale-up, and production
Moderna, Inc. announced in an 8-K filing that the FDA issued a Refusal-to-File (RTF) letter for its Biologics License Application (BLA) for mRNA-1010, its investigational seasonal influenza vaccine.
Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing revenue growth driven by Dupixent and EYLEA HD. Q4 revenues increased 3% to $3.
Merck (MRK) reported its Q4 and full-year 2025 financial results, highlighting strong performance in oncology (driven by KEYTRUDA), animal health, and increasing contributions from newer products like...
Pfizer (PFE) released its Q4 and full-year 2025 financial results, reporting full-year revenues of $62.6 billion, a 2% operational decline year-over-year, although non-COVID product revenues grew 6%.